PT - JOURNAL ARTICLE AU - Benjamin, Ryan L. TI - Basic reproduction number projection for novel pandemics and variants Ancestral SARS-CoV2 ℛ<sub>0</sub> projection AID - 10.1101/2022.07.03.22277191 DP - 2022 Jan 01 TA - medRxiv PG - 2022.07.03.22277191 4099 - http://medrxiv.org/content/early/2022/07/05/2022.07.03.22277191.short 4100 - http://medrxiv.org/content/early/2022/07/05/2022.07.03.22277191.full AB - The recently derived Hybrid-Incidence Susceptible-TransmissibleRemoved (HI-STR) prototype is a deterministic epidemic compartment model and an alternative to the Susceptible-Infected-Removed (SIR) model prototype. The HI-STR predicts that pathogen transmission depends on host population characteristics including population size, population density and some common host behavioural characteristics.The HI-STR prototype is applied to the ancestral Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) to show that the original estimates of the Coronavirus Disease 2019 (COVID-19) basic reproduction number (ℛ0) for the United Kingdom (UK) could have been projected on the individual states of the United States of America (USA) prior to being detected in the USA.The Imperial College London (ICL) group’s ℛ0 estimate for the UK is projected onto each USA state. The difference between these projections and ICL’s estimates for USA states is either not statistically significant on the paired student t-test or epidemiologically insignificant.Projection provides a baseline for evaluating the real-time impact of an intervention. Sensitivity analysis was conducted because of considerable variance in parameter estimates across studies. Although the HI-STR predicts that in-creasing symptomatic ratio and inherently immune ratio reduce ℛ0, relative to the uncertainty in the estimates of ℛ0 for the ancestral SARS-CoV2, the projection is insensitive to the inherently immune ratio and the symptomatic ratio.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors